Cullinan Therapeutics, Inc.

NASDAQ:CGEM

Medical - Pharmaceuticals

Healthcare
$9.01 +4.29%

+$0.62 today

Market cap
$584.94M
Beta
0.01
P/E (TTM)
-4.0
EPS (TTM)
-$3.73
52W Low $5.68High $16.74

Volume 1.06M

Average 0.99M

CGEM Depreciation & Amortization

Non-cash expense that spreads the cost of physical and intangible assets over their useful lives.

Cullinan Therapeutics, Inc.NASDAQ: CGEM

Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026

Depreciation & amortization grows in line with its trailing trend

Q1 FY2026 depreciation & amortization of $79K rose 3.9% year over year, ahead of the +2.6% change in trailing-twelve-month depreciation & amortization. Sequentially, it rose 0.0% from the prior quarter. Over 3 fiscal years it compounded at +49.5% a year.

Context

  • Depreciation & amortization increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +3.9% holds above the trailing-twelve-month pace of +2.6%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$79K+0.0% QoQ
Last fiscal yearDec 2025
$311K+1.6% YoY
LTMMar 2026
$314K+2.6% YoY
Depreciation & Amortization past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+3.9%——
1 year+1.6%——
3-year CAGR+49.5%——
5-year CAGR——
10-year CAGR——

Depreciation & Amortization history

USD · from the income statement

Latest · FY2025
311K USD
Year-over-year change
+1.6%
4-year CAGR
+55.6%

Depreciation & Amortization vs competitors

How CGEM compares with its peers on the latest reported figures

  • Peers report in different currencies, so depreciation & amortization is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +2.6% is the 2nd highest of 9, against a peer median of -7.9%.
  • Over three fiscal years its annual growth of +49.5% compares with a peer median of +16.3%.
CGEM Competitors
Depreciation & Amortization for CGEM and competitors
Company Period LTM YoY 3-year CAGR% of revenue
LEGNLegend Biotech CorporationLTM Sep 2026$50.27M USD+111.9%+16.3%3.7%
NRIXNurix Therapeutics, Inc.LTM Aug 2026$14.4M USD-22.3%+20.4%2.1%
IMTXImmatics N.V.LTM Mar 2026€12.04M EUR-2.6%+21.9%32.3%
XNCRXencor, Inc.LTM Jun 2026$10.17M USD-10.7%+6.1%9.7%
MGNXMacroGenics, Inc.LTM Mar 2026$7.09M USD-5.1%-15.4%4.5%
JANXJanux Therapeutics, Inc.LTM Mar 2026$2.03M USD-0.8%+34.1%9.4%
ADCTADC Therapeutics S.A.LTM Mar 2026$1.19M USD-63.3%-7.7%1.5%
ALXOALX Oncology Holdings Inc.LTM Mar 2026$645K USD-25.8%+27.3%—
CGEMCullinan Therapeutics, Inc.LTM Mar 2026$314K USD+2.6%+49.5%—
AVBPArriVent BioPharma, Inc. Common StockLTM Mar 2026$0 USD———
CGENCompugen Ltd.LTM Mar 2026$0 USD—-0.5%0.0%
Peer median (excluding CGEM) —-7.9%+16.3%4.1%

Competitors are the stored peer set for CGEM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue18.94M0000
Cost of Revenue000306K0
Gross Profit18.94M00(306K)0
Gross Margin100.0%————
Research & Development57.75M91.95M148.16M142.9M187.4M
Selling, General & Admin29.15M40.19M42.49M53.71M54.25M
Operating Expenses86.9M(144.65M)191.09M196.61M241.65M
Depreciation & Amortization53K93K310K306K311K
EBITDA(67.43M)(132.04M)(190.34M)(167.15M)(219.57M)
EBITDA Margin-356.0%————
Operating Income(67.95M)144.65M(191.09M)(196.92M)(241.65M)
Operating Margin-358.7%————
Interest Income477K6.61M21.63M29.66M22.21M
Interest Expense00000
Other Income / Expenses469K6.67M21.87M29.46M21.77M
Income Before Tax(67.49M)151.32M(169.22M)(167.46M)(219.88M)
Pre-Tax Margin-356.3%————
Income Tax Expense042.12M(14.12M)117K0
Net Income(65.57M)111.21M(153.16M)(167.38M)(219.88M)
Net Margin-346.1%————
EPS (Basic)(1.48)2.46(3.69)(3.11)(3.72)
EPS (Diluted)(1.48)2.38(3.69)(3.11)(3.72)
Weighted Avg Shares44.29M45.16M41.51M53.77M59.05M
Weighted Avg Shares (Diluted)44.29M46.64M41.55M53.77M59.05M

Cullinan Therapeutics, Inc.

NASDAQ:CGEM

Intrinsic Alpha fair value

Locked

Current Price

$9.01

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.